We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Study Confirms Association of AD and High Levels of LDL Cholesterol

By LabMedica International staff writers
Posted on 10 Jun 2019
Print article
Image: A molecule model of Apo E (Photo courtesy of Wikimedia Commons).
Image: A molecule model of Apo E (Photo courtesy of Wikimedia Commons).
High LDL cholesterol levels have been linked to the risk of developing early-onset Alzheimer's disease (AD).

Early-onset Alzheimer's disease (EOAD), which manifests in individuals younger than age 65, accounts for about 10% of all Alzheimer's cases. In late-onset AD, elevated circulating cholesterol levels increase AD risk even after adjusting for the apolipoprotein E epsilon4 (APOE E4) allele, a major genetic factor for AD and elevated cholesterol levels; however, the role of circulating cholesterol levels in EOAD is unclear.

Investigators at Emory University (Atlanta, GA, USA) studied the association between circulating cholesterol levels and EOAD in order to identify genetic variants underlying this possible association. For this study, the investigators sequenced specific genomic regions of 2,125 subjects, 654 of whom had EOAD and 1,471 controls. They also determined LDL cholesterol levels in blood samples from 267 participants. To determine the underlying genetic variants, APOB, APP, PSEN1, and PSEN2 genes were sequenced in samples from 2125 EOAD cases and controls.

Results revealed that of the 2125 samples that underwent genetic sequencing, 1276 were from women and 654 were from patients with EOAD. APOE E4 explained 10.1% of the variance of EOAD. After controlling for APOE E4, EOAD cases had higher levels of total cholesterol, LDL cholesterol and the LDL protein Apo B than controls in 267 frozen samples. Approximately 3% of EOAD cases carried known AD-causing mutations. Gene-based rare variant burden testing in 2066 samples showed that rare APOB coding variants were significantly more abundant in EOAD cases after adjusting for sex and APOE E4.

The results did not find a link between HDL (high-density lipoprotein) cholesterol levels and EOAD, and only a very slight association between the disease and triglyceride levels.

"The big question is whether there is a causal link between cholesterol levels in the blood and Alzheimer's disease risk," said first author Dr. Thomas Wingo, assistant professor of neurology and human genetics at Emory University. "The existing data have been murky on this point. One interpretation of our current data is that LDL cholesterol does play a causal role. If that is the case, we might need to revise targets for LDL cholesterol to help reduce Alzheimer's risk. Our work now is focused on testing whether there is a causal link."

The study linking EOAD to high LDL cholesterol levels was published in the May 28, 2019, online edition of the journal JAMA Neurology.

Related Links:
Emory University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.